Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
ACS Chem Biol. 2010 Nov 19;5(11):1053-63. doi: 10.1021/cb100161u.
Protein arginine N-methyltransferases (PRMTs) catalyze the post-translational methylation of arginine residues within substrate proteins. Their roles in the epigenetic regulation of gene expression make them viable targets for drug discovery. Peptides containing a single arginine residue substituted at the guanidino nitrogen (N(η)) with an ethyl group bearing zero to three fluorine atoms (R1-1, -2, -3, and -4) have been synthesized and tested for methylation and inhibition activity with PRMT1, PRMT6, and CARM1. Only the nonfluorinated R1-1 peptide is methylated by PRMT1, demonstrating that the N(η)-substituted arginine is accommodated by its active site. The R1-1 ethyl-substituted guanidine N(η) was further identified as the methylation site via mass spectrometry. Although weak inhibitors of CARM1, R1-1, -2, -3, and -4 are potent inhibitors of PRMT1 and PRMT6. These peptides are more potent against PRMT1 than product inhibitor peptides, showing that N(η)-substituted arginyl peptides do not work by a purely product inhibitor mechanism. A trend of increasing potency with an increase in the number of fluorine atoms is observed for PRMT1, which may result from the corresponding change in the guanidino dipole moment. Modeling of the ethyl-arginine moiety of the R1-1 peptide demonstrates that the active site of PRMT1 accommodates such modifications. N(η)-Substituted arginyl peptides represent lead compounds for the further development of inhibitors that target the methyl-acceptor binding site of PRMTs.
精氨酸 N-甲基转移酶(PRMTs)催化底物蛋白中精氨酸残基的翻译后甲基化。它们在基因表达的表观遗传调控中的作用使它们成为药物发现的可行靶点。已经合成并测试了含有单个精氨酸残基的肽,该残基的胍基氮(N(η))用零到三个氟原子取代(R1-1、-2、-3 和-4),用于 PRMT1、PRMT6 和 CARM1 的甲基化和抑制活性。只有未氟化的 R1-1 肽被 PRMT1 甲基化,这表明 N(η)取代的精氨酸被其活性位点容纳。通过质谱进一步鉴定 R1-1 乙基取代胍基 N(η)为甲基化位点。尽管是 CARM1 的弱抑制剂,R1-1、-2、-3 和-4 也是 PRMT1 和 PRMT6 的有效抑制剂。这些肽对 PRMT1 的抑制作用强于产物抑制剂肽,表明 N(η)取代的精氨酰肽不是通过纯产物抑制剂机制起作用的。观察到 PRMT1 的活性随氟原子数的增加而增加的趋势,这可能是由于胍基偶极矩的相应变化所致。R1-1 肽的乙基-精氨酸部分的建模表明 PRMT1 的活性位点容纳了这种修饰。N(η)取代的精氨酰肽代表了进一步开发靶向 PRMTs 甲基受体结合位点的抑制剂的先导化合物。